PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical...

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Anaplastic lymphoma kinase (ALK) and ROS1 fusions drive certain lung cancers.
• Existing ALK inhibitors face challenges with resistance mutations and brain metastases.
• Novel therapeutic strategies are needed for advanced ALK-driven non-small cell lung cancer (NSCLC).

Purpose of the Study:

• To evaluate the preclinical efficacy and safety of PF-06463922, a novel ALK/ROS1 inhibitor.
• To assess PF-06463922's activity against known ALK resistance mutations.
• To determine PF-06463922's effect on brain metastases and overall survival in preclinical models.

Main Methods:

• In vitro biochemical and cellular assays to determine potency against ALK/ROS1 and mutations.
• In vivo studies using patient-derived xenografts and genetically engineered mouse models.
• Pharmacokinetic and safety assessments in preclinical species.

Main Results:

• PF-06463922 demonstrated superior potency against a broad spectrum of ALK mutations, including G1202R.
• Significant regression of EML4-ALK-driven brain metastases was observed.
• PF-06463922 exhibited favorable selectivity and safety profiles in preclinical evaluations.

Conclusions:

• PF-06463922 is a potent, brain-penetrant ALK/ROS1 inhibitor with promising preclinical data.
• It shows potential efficacy in patients with ALK-driven lung cancers, including those with resistance mutations or brain metastases.
• Further clinical investigation of PF-06463922 is warranted for ALK-positive NSCLC treatment.